Treatment for substance use disorders: the Belgian Treatment Demand Indicator registration protocol by Jérôme Antoine et al.
STUDY PROTOCOL Open Access
Treatment for substance use disorders: the
Belgian Treatment Demand Indicator
registration protocol
Jérôme Antoine*, Karin De Ridder, Els Plettinckx, Peter Blanckaert and Lies Gremeaux
Abstract
Background: Registration of patients with substance use disorders is of key importance to get insights and to
study trends in patients characteristics and substance use patterns. The Treatment Demand Indicator (TDI) is
gathering this information at European level since 2000. In Belgium, this registration started at national level
in 2011 and an increasing number of facilities of different types are participating in this data collection since then.
Methods/Design: This surveillance register collects information on every treatment episode started by patients for
their substance use disorder. Information is collected on socio-demographic characteristics of the patient, treatment
history and substance use patterns. Patients are identified uniquely using their national identification number in order
identify multiple episodes followed by a same person. A large range of treatment facilities have the possibility
to participate in this registration to allow a wide coverage of the population.
Discussion: The objective of the paper is to facilitate the use of data by authorities or researchers by correctly
describing all aspects of the indicator. The case definition, the variables collected and the way data should be reported
are of key importance to use and interpret the data correctly. An overview of the data registered in 2014 gives also an
idea of the content of the database. The article also pictures the strengths and limitations of the register and foresees
some future improvements.
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Background
Drug policies and action plans require sound and com-
prehensive evidence on what are the main issues in the
drug problematic and how to intervene. In order to ob-
tain a better understanding of the different aspects of
the drug phenomenon as well as the impact of related
measures, the information exchange, data collection and
monitoring of the drug situation at the European level
are of great importance [1–3].
Illicit substance use disorders in the general popula-
tion have a low prevalence. The last Health Interview
Survey performed in 2013 in Belgium showed that 2,6 %
of the population (15–64 years) is currently (in the last
30 days) using cannabis and 0,8 % has used other illicit
substances during the last year [4]. For alcohol, the
prevalence is much higher. The Health Interview Survey
shows that 10,5 % of the population has a problematic
use of alcohol [4]. But such estimations in the general
population are often difficult to process due to methodo-
logical concerns: representativeness of the sample is
often not reached and substance-use disorders are diffi-
cult to assess by self-administered questionnaire. There-
fore data collected when people with substance use
disorders come into contact with health professionals is
consequently a main information source for drug epi-
demiology and demand reduction [5].
The Treatment Demand Indicator (TDI) is an epi-
demiological indicator collected in a standardised way in
all 28 member states of the European Union, Turkey
and Norway on behalf of the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA).
Through the use of this indicator, insights can be gained
into the characteristics, risk behaviours and drug use
patterns of people admitted into treatment for their drug
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use which supports the follow up, ideally in combination
with other drug indicators, of trends in the extent and
patterns of drug use [5].
The European protocol
A common protocol for collecting data on people enter-
ing drug treatment has been first defined by the Pompi-
dou Group (PG), who coordinated studies at city level
(in Dublin and London in 1991) and a developmental
project in 11 cities [6]. The PG protocol was published
in 1994 [7] and was first implemented at city level and
then at country level. In 1994, the EMCDDA was estab-
lished, and took responsibility for collecting European
treatment demand data. The Treatment demand indica-
tor 2.0 protocol [8] was published based on a revision of
the first PG protocol. It was preceded by a feasibility as-
sessment concerning methodology and data collection
[9] and by an evaluation of national experiences of data
reporting using the TDI [10]. Since 2000, the EMCDDA
has been implementing the data reporting from the
European Union (EU) Member States and adopted for-
mal agreements with the Member States to stimulate
and facilitate data collection and reporting from national
to European level.
After 10 years of data collection at the European level
using this protocol, modification were required so the
TDI could better reflect the changes that have occurred
over this period not only in the situation of drug use,
but also in the treatment system and national and inter-
national information systems. Therefore, a third version
of the protocol has been set up in 2013 [6]. Today, the
indicator is collected in 30 countries (28 member states
of the EU, Norway and Turkey) and provides informa-
tion on almost 400,000 patients in the EU [11].
The Belgian protocol
Due to organisational problems, Belgium only started
the standardization of the TDI data collection in 2006
when all Ministers with a health competencies decided
to coordinate the registration of treatment demand and
built a specific national protocol based on the European
protocol version 2 [12, 13]. Before this time, different
initiatives to collect information at different levels (re-
gion, city, group of centres,…) on treatment demands of
drug use problems took place sometimes since a long
time [14–17]. But these registrations were too different
to provide a coherent national view of the phenomenon.
Recently, this protocol has been updated in order to
include the necessary changes implied by the use of the
third European protocol [18]. In the national protocol,
the Scientific Institute of Public Health (WIV-ISP) has
been appointed as coordinator of the registration and
has been asked to develop flexible, secured technical
tools to facilitate the data registration in respect with na-
tional privacy rules [19–21].
The standardized TDI data collection actually started
in Belgium in 2011 based on protocol version 2 and
since 2015 based on version 3.
Methods/Design
Case definition
In order to better standardize the data collection, a clear
case definition is needed and all the terms used need also
an explanation in order to avoid confusing interpretation.
The Belgian TDI registration collects information on
every treatment episode (d) started by a person (a) in a
treatment centre (b) for his/her alcohol or illicit drug
use (c).
(a) The registration concerns all individuals without
any restriction based on age or nationality. The only
condition is that the patient has to have a face-to-face
contact with a treatment centre for their substance use
problem. Therefore, persons in contact by telephone, let-
ter, internet or contacts which were done by the family
of the patient are not included in the registration. Fur-
thermore, every patient has to be informed of the regis-
tration for privacy purposes. Especially the existence and
objectives of the register, the coordinates of the person
responsible for the data, the destination of the data, the
right to access and correct their own data have to be
mentioned. A patient can resign to participate to this
registration by written refusal.
(b) Treatment centres are defined as facilities or prac-
titioners providing treatment for drug or alcohol addic-
tion. These centres offer outpatient or inpatient services,
either specialized in addiction treatment or included in
larger scale facilities targeting different groups of people.
This type of care is sometimes recognized within a con-
vention of authorities such as the national institute for
health and disability insurance (NIHDI). The registration
of TDI in Belgium is only mandatory for some groups of
centres: centres within the NIHDI convention since
2011, centres for mental health in Flanders since 2013,
hospitals since 2015, centres with agreement from the
Walloon Region since 2011. As a consequence, the num-
ber of participating centres varies from year to year and
the coverage of the registration can evolve.
Non-professional support groups, centres providing
only harm reduction activities, social reintegration, pre-
vention services or outreach activities are not considered
as treatment centres.
In order to have an overview of the data collected over
time by centres, Table 1 shows the number of registered
treatment episodes and the participation rate among all
kind of treatment centres potentially be eligible for the
TDI registration. These centres are classified in categor-
ies describing the type of service as well as the
Antoine et al. Archives of Public Health  (2016) 74:27 Page 2 of 8
specialized or general aspect of the facility. Coverage in
specialized services is much better than in general care
settings for both outpatient and inpatient settings. On
the other way general practitioners who are playing a
major role in detecting and managing substance abuse
are not covered by the indicator. Hospitals are increas-
ingly involved in the data collection since 2011 based on
pilot projects. From 2015 on a royal decree officialise
the data collection in all Belgian hospitals.
(c) Treatment is defined as any activity targeting a per-
son with substance use problems directly in order to ob-
tain results in terms of reducing or eliminating these
problems. Possible activities include detoxification or ab-
stinence, substitution treatment, long-term alcohol/drug
programmes, psychotherapy, counselling, structured
treatment with strong social component, medically
assisted treatment, non-medical interventions, specific
treatment in prison or interventions aimed at reducing
drug-related harm if they are included in a planned
programme. Treatment of consequences of substance
use in which the use of alcohol or drug is not the main
reason for seeking help and sporadic interventions not
included in a planned programme are not considered as
a treatment. Unlike the European protocol, the Belgian
protocol includes alcohol in the list of primary sub-
stances. The drug types that are considered : a) opioids
(category) including heroin and misuse of methadone,
buprenorphine, fentanyl (or illicit) or other opioids; b)
cocaine (category) including powder cocaine, crack co-
caine or other cocaine; c) stimulants, other than cocaine
(category) including amphetamines, methamphetamines,
MDMA or derivatives, mephedrone or other stimu-
lants; d) hypnotics and sedatives (category) including
misuse of barbiturates and benzodiazepines, GHB/GBL
or other hypnotics and misuse of sedatives; e) halluci-
nogens (category) including LSD, ketamine or other
hallucinogens; f ) volatile inhalants; g) cannabis (category)
including marijuana (herb), hash (resin) or other cannabis
and other substances not included above. Tobacco and
the use of the substances for a medical treatment or for
other somatic or psychiatric reasons are excluded. Non-
substance addiction such as gaming or internet addiction
is also not part of this registration.
(d) Registration has to be done for every treatment
episode defined as the period between the start of the
treatment and the end of activities in the context of the
program prescribed. The start of the episode is the first
face-to-face contact between the professional and the
patient. The end of the treatment episode is defined dif-
ferently in outpatient and inpatient settings. The end of
the episode occurs in outpatient settings when the pa-
tient stops attending treatment for a period longer than
6 months. In inpatient settings, end of treatment occurs
when the patient leaves the centre and no further admis-
sion is foreseen. The registration of new treatment epi-
sodes is continuous through registration years meaning
that a patient with regular visits in an ambulatory setting
without a 6 months break, will be registered in TDI only
once, namely the first contact with that specific treat-
ment centre.
Table 1 List, participation rate and number of registration episodes of eligible treatment centres in Belgium during the 4
registration years of TDI
Category Description Number of episodes (Participation rate of centres) within a
given registration year
2011 2012 2013 2014
Outpatient services Specialized drug
treatment centres
Day-care centres 2859 (64 %) 2726 (73 %) 3112 (82 %) 3131 (82 %)
Consultation centres 416 (31 %) 573 (44 %) 735 (47 %) 1297 (56 %)
Medical and social care centres 1592 (100 %) 1690 (100 %) 1936 (100 %) 1892 (100 %)
General/Mental health
care
Centres for mental health 24 (1 %) 191 (4 %) 2306 (19 %) 2308 (17 %)
General practitioners 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Psychologists, psychiatrists in
private practice
0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Medical houses 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Prisons Health units in prison 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Inpatient services Hospital-based residential
drug treatment
Psychiatric hospitals 742 (26 %) 3460 (37 %) 4301 (39 %) 5834 (52 %)
General hospitals 1055 (10 %) 2966 (22 %) 4171 (24 %) 7381 (38 %)
Specialized residential treatment
(non-hospital based)
Specialized crisis centres 1086 (100 %) 1027 (100 %) 1059 (100 %) 1066 (100 %)
Therapeutic communities or
long-duration residential centre
799 (100 %) 682 (100 %) 727 (100 %) 685 (100 %)
Supervised housing Psychiatric care houses 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
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Registration system
The WIV-ISP collects and manages data in a secured
way at national level and has therefore developed two
options for data transfer. The registration module con-
sists of an online form with restricted access for treat-
ment centres in order to encode and manage their data
record by record. The repository module is a secured
mailbox through which treatment centres can send
structured files containing a complete dataset for a given
registration year.
The national identification number (NIN) of the pa-
tient has to be coded in both options to respect privacy
rules before data is stored in the database. The coding is
done by a trusted third party (eHealth) and occurs by
the run of an algorithm on the field containing the vari-
able for the registration module or on the first specific
part of the structured file for the repository module.
In order to better structure the data collection, records
from a given year have to be sent by treatment centres
before end of March of the next year.
In the next future, this registration system will be inte-
grated into the Healthdata.be process [22] which is a
standardized, secured, cross register way of collecting
medical data in Belgium. It combines both a database in-
tegration and a specific registration tool.
Collection of the variables
At the start of every treatment episode, a form is
completed by a professional during a face-to-face
interview with the patient. Questions are related to
the identification of the centre, identification of the
patient, description of the patient’s socio-demographic
and economic status, treatment characteristics and sub-
stance use pattern. The questions have slightly changed
between the two versions of the Belgian protocol (version
2 (2011–2014) and version 3 (2015-present)). Some ques-
tions are also specifically included for centres with a given
convention (NIHDI, Hospitals or Walloon Region (WR)).
Table 2 summarizes the different variables included in the
two versions of the basic form and additional variables
corresponding to specific convention centres (Hospitals,
NIHDI convention, Walloon Region). A reference to the
number of the question is provided in the text below.
Identification of the centre is made at the level of the
centre itself (Q1) and at the level of a unit or program
or satellite within the centre (Q2). The type of treatment
unit or program (Q3) and its geographic localisation
(Q5) allows to characterize provided treatment and to
differentiate geographic areas. The type of hospital bed
(Q4) and the distance between the treatment centre and
the place of residence (Q6) is also asked in a limited
number of centres.
The patient should be identified preferably with the
unique NIN (Q8). This number is unique for every
Belgian citizen or people having social security rights for
non-Belgian citizens. Its use within the TDI registration
allows to avoid double counting by identification of the
person in different centres at national level and to follow
patients between their different treatments episodes. If
the NIN of the person is not available or if the patient
doesn’t want this number to be registered, it is possible
to carry out the registration by mentioning it (Q7).
Variables such as socio-demographic data (sex (Q9),
age (Q10) and nationality (Q11)) and socio-economic in-
formation (type of accommodation (Q12), type of house-
hold (Q13, Q14), educational level (Q15), work and
income situation (Q16, Q17)) describe the characteristics
of the patient. These variables allow identification of epi-
demiological groups of patients and assessment of the
social relations and stress of the stability of the living
situation of the patient.
The start date of the current treatment episode (Q18),
the fact that the client already followed previous treat-
ment for substance use before (Q19), the main source of
referral (Q20) and his/her substitution treatment situ-
ation (Q21, Q22, Q23) are used to describe the treat-
ment situation of the patient and for questions on
previous treatment to identify the first treatment en-
trants. Two questions on diagnosis (Q24) and treatment
objectives (Q25) are part of the questionnaire for
hospitals.
The variables about the pattern of substance use
show important differences between the second and
third version of the protocol. In the second version,
the primary substance is identified first (Q28) and
then the other used substances (Q29). On the con-
trary, all substances causing problem are identified
first (Q26) in version 3 and then eventually (Q27) the
primary substance is mentioned (Q28). In this last
version, polydrug use (Q30) is identified when more
than one substance is causing problem (Q26). Three
questions are afterwards related to the patterns of use
of the primary substance (Q31, Q32, Q33). Risk be-
haviour characteristics are then pictured with ques-
tions on injecting status (Q34, Q35, Q36) and sharing
of syringes (Q37, Q38). In addition, sharing of para-
phernalia (Q39, Q40) is asked in some centres.
Table 3 gives a basic view on the content of the
database based on some results from the TDI regis-
tration in 2014 by type of services. This table shows
big differences between the different services in the
type of clients seen, their history of treatment and ad-
diction profile.
Analysis and reporting
Quality checks are performed directly in the registration
module or after reception of the file from the repository
module. Checks are related to the content of the variable
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Table 2 List of variables in the different versions and types of questionnaire of the Belgian TDI protocol
Nr Variable description Protocol version 2 (2011–2014) Protocol version 3 (2015-present)
Identification of the centre
Q1 Name of the centre In all versions In all versions
Q2 Name of the unit/program/satellite In all versions In all versions
Q3 Type of unit/program/satellite In all versions In all versions
Q4 Type of hospital bed where the patient is hospitalized / Version Hospitals
Q5 Arrondissement where the patient is treated In all versions In all versions
Q6 Distance between centre and residence place Version NIHDI Version NIHDI +Walloon region
Identification of the patient
Q7 Type of identification In all versions In all versions
Q8 Identification number In all versions In all versions
Description of the client
Q9 Sex In all versions In all versions
Q10 Age at beginning of the treatment episode In all versions In all versions
Q11 Nationality In all versions Version NIHDI +Walloon region
Q12 Main type of accommodation during the last 30 days In all versions In all versions
Q13 Main type of household during the last 30 days In all versions In all versions
Q14 Responsibility of children during the last 30 days In all versions In all versions
Q15 Highest educational level achieved In all versions In all versions
Q16 Main work situation during the last 30 days In all versions In all versions
Q17 Main income situation during the last 30 days / In all versions
Description of the treatment
Q18 Date of the start of treatment In all versions In all versions
Q19 Status of previous addiction treatment In all versions In all versions
Q20 Source of referral for this treatment episode In all versions In all versions
Q21 Lifetime substitution treatment In all versions In all versions
Q22 Kind of substitution treatment In all versions In all versions
Q23 Age at first substitution treatment / In all versions
Q24 Main diagnosis of substance use Version Hospitals Version Hospitals
Q25 Treatment objectives Version Hospitals Version Hospitals
Substance use patterns
Q26 Current problematic substances / In all versions
Q27 Existence of primary substance / In all versions
Q28 Primary substance In all versions In all versions
Q29 Other substances used In all versions /
Q30 Polydrug use problem / In all versions
Q31 Age at first use of primary substance In all versions In all versions
Q32 Main route of administration of primary substance In all versions In all versions
Q33 Main frequency of use of the primary substance In all versions In all versions
Q34 Injecting status In all versions In all versions
Q35 Age at first injecting / In all versions
Q36 Last injecting occurrence / In all versions
Q37 Share of needle status / In all versions
Q38 Last share of needle occurrence / In all versions
Q39 Share of paraphernalia / Version Walloon Region
Q40 Last share of paraphernalia occurrence / Version Walloon Region
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(values in every variable), and to compatibility between
variables (the value in one variable is dependent on the
value in others). No quality checks are currently made
on a longitudinal basis (comparing data of the same pa-
tient in time) but it will be possible to implement this in
the future.
Data is stored in a datawarehouse where each record
correspond to a treatment episode. Each treatment epi-
sode is identified by the coded identification number of
the patient, identification number of the treatment unit
and the start date of treatment.
For those registered with the NIN it’s possible to iden-
tify double records being the same patient registered in
the same unit at the same start date of treatment. It’s
also possible to identify treatment episodes for the same
person over time.
Data from the database can be used either as the num-
ber of treatment episodes or the number of patients.
The number of patients however is an overestimation as
all anonymously recorded registrations are counted as
separate patients.
Data providers have access to their raw data registered
in the database in order to allow them to check and per-
form analysis on their own data. In addition a reporting
module has been developed to present the data in tables
and figures, comparing the descriptive statistics with re-
sults of other similar centres. Some authorities also re-
ceive raw data concerning treatment centres under their
responsibility. As the collection of the indicator info is
commissioned by the EMCDDA, an obligatory report is
sent annually to the EMCDDA in aggregated tables. Re-
ports on specialized centres with NIHDI convention
have been written annually since 2011 [23–26].
A steering committee (CocoTDI), including represen-
tatives of treatment centres, authorities and national
experts is appointed to follow-up the registration and
provides advices on the use and registration of data.
Use of TDI data
TDI data must be used for epidemiological purposes
only. The use of these data in order to assess administra-
tive objectives is not possible. Data is well adapted to de-
scribe characteristics of groups of patients starting a
treatment for substance use, to assess patterns of use, to
follow trends in time and to describe the use of services
by patients. In combination with other databases, further
in-depth analyses will also be possible.
The use of NIN makes also possible the linkage be-
tween different databases. A recent study proposed to
link the TDI database with the health insurance data-
bases [27].
At European level, the TDI data makes comparisons
between countries possible for a given phenomenon like
the recent study on heroin use and heroin injection [28]
or the study on trends of injecting drug use [29].
The interpretation of TDI data should be made with
caution as data concern a very specific population. The
use of absolute numbers should always consider the
coverage of the data collection and only similar data can
be compared. The terminology used to interpret and
clarify the data should always be chosen carefully. For
example, it’s sometimes easier to speak more generally
about drug user whereas TDI data is only about those
starting a treatment. Furthermore the clients registered
in TDI cannot be automatically considered as problem-
atic users according to the most common definitions.
A website is dedicated to the technical aspects of the
TDI registration in Belgium (https://tdi.wiv-isp.be) and
provides also a list of publications based on TDI data.
From data collection 2015 on, a national report will
Table 3 General description on the content of the TDI database in 2014 by type of service









Proportion of use of the national
identification number
70 % 60 % 66 % 73 %
Proportion of women 19 % 26 % 32 % 18 %
Mean age 32 NA 43 33
Top 3 problematic substances 1. Cannabis (31 %) 1. Alcohol (51 %) 1. Alcohol (72 %) 1. Opiates (33 %)
2. Opiates (29 %) 2. Cannabis (27 %) 2. Opiates (7 %) 2. Cocaine (20 %)
3. Cocaine (14 %) 3. Cocaine (6 %) 3. Cannabis (7 %) 3. Alcohol (18 %)
Proportion first treatment ever 44 % 54 % 24 % 13 %
Top 3 sources of referral 1. Self-referred (40 %) 1. Justice (25 %) 1. Self-referred (47 %) 1. Self-referred (46 %)
2. Justice (22 %) 2. Self-referred (19 %) 2. Hospital (14 %) 2. Addiction centre (24 %)
3. Other (16 %) 3. Hospital (17 %) 3. Other (14 %) 3. Hospital (12 %)
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present the detailed situation of the treatment demand
in Belgium. A procedure is going to be approved in
order to standardize and clearly document the requests
for data from the TDI database for specific research.
Discussion
The TDI database is a valuable epidemiological data-
base as it represents one of the rare reliable data pools
available on drug users in treatment. Its national and
European range and its longitudinal objective make it
also an interesting tool to compare between European
countries, subgroups of patients, specific geographic
areas and over time.
Every country has to adapt the European protocol
to its own specific requirements and possibilities. The
Belgian TDI protocol is the result of a consensus with
national experts and authorities, meeting as much as
possible the European standards. In order to safe-
guard some national specificities, variants of the ques-
tionnaire are existing to target specific questions for a
limited number of centres. Nevertheless some vari-
ables from the European version have not been con-
sidered in the Belgian version (such as questions on
testing for infectious diseases), while some items have
been differently implemented (such as polydrug use).
Also other items like for example alcohol as primary
substance are integrated.
The TDI protocol has been officially approved by all
ministers of public health and published in the official
gazette which gives an official status and a clear visibility
for all actors concerned. The approvals from the privacy
commission and its future integration in a database sys-
tem of Healthdata.be also offers a token of a correct way
of dealing with personal data.
The strength of this registration is the use of the
NIN as unique identification number of clients as this
increases the utility of these data. In addition the
identification of double records and treatment epi-
sodes of a client in centres at national level, this per-
mits to follow up of a client’s pathway through
treatment facilities and the evolution of their patterns
of use in time. The possibility to link these data with
other databases taken the privacy rules into account
at any time, creates the possibility to use this indica-
tor for in-depth scientific analyses. However the regis-
tration of the national identification number is not
mandatory. This allows to register data even from pa-
tients not having a NIN nor willing to share it. In
consequence, not all potential duplicates can be ex-
cluded and about 30 % of the data cannot be linked
to other treatment episodes within the TDI register
nor to other databases.
Even though the representativeness of demand in spe-
cialized centres and in general/psychiatric hospitals is
relatively good, TDI is facing a lack of registration in
the non-specialized sector (medical house, centres for
mental health, private practice,…). Consequently, the
tool offers a valuable information about drugs or alco-
hol users reached by specialized care centres and gen-
eral/psychiatric hospitals but the profile of patients may
not currently be generalised to the whole patients seek-
ing help for drug use as we observe great differences in
the patient’s characteristics among the sectors. Enhance
the representativeness of the general sector is one of
the main action to tackle in the future.
More knowledge on the coverage aspects of the indi-
cator is needed to better evaluate the validity of the
available information. Coverage can be interpreted in
two ways: as “external coverage” being the number of
centres reporting compared to the total number of cen-
tres in the country as well as “internal coverage” being
the number of individuals and of treatment episodes
registered compared with the total number of treat-
ment episodes started. This aspect could be targeted
in the future through the use of a regular treatment
facility survey which is in development.
The TDI registration is sometimes criticized for having
a definition of ‘treatment’ or ‘treatment centre’ that is
too limited. Contacts in harm reduction settings (syringe
exchange programmes) or treatment of complications of
drug use are not registered. From an international per-
spective, further development of the TDI indicator is al-
ways possible and if a consensus can be reached, the
protocol could be reviewed in order to better assess
these issues in a structured and coordinated way.
The present TDI indicator reflects the incidence of new
started treatments for a drug and/or alcohol problem. On
the contrary the treatment prevalence, being the total
number of clients in treatment (including also long-term
treated clients), cannot be assessed with the present TDI
indicator. The prevalence is interesting for assessment of
actual workload in treatment services. Such a new indica-
tor could relatively easily be combined with the TDI regis-
tration again based on the use of the NIN.
TDI in Belgium has been implemented since 2011 and
is now almost functioning in a routine way. This is the
first time a national overview is approached that gives
information on the demands for substance related treat-
ment. The use of the data should be supported in the fu-
ture to better demonstrate its relevance in health care
research and policy making and to promote the data
registration at the level of field organizations with focus
on quantity as well as on quality.
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